Boston Scientific price target raised to $12 from $9 at JMP Securities JMP Securities increased its price target on Boston Scientific as the firm believes after speaking with experts that S-ICD devices can be used in 50% of de novo implant cases, up from its previous estimate of 30%. The firm's FY13 and FY14 earnings estimates for the company are well above consensus levels and it reiterates an Outperform rating on the shares.
Boston Scientific has a conference call hosted by JPMorgan JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on May 17 at 11 am.